SYRE logo

SYRE
Spyre Therapeutics Inc

2,156
Mkt Cap
$6.26B
Volume
1.11M
52W High
$78.80
52W Low
$13.93
PE Ratio
-31.17
SYRE Fundamentals
Price
$73.50
Prev Close
$72.11
Open
$71.83
50D MA
$63.94
Beta
1.78
Avg. Volume
1.42M
EPS (Annual)
-$1.98
P/B
11.25
Rev/Employee
$0.00
$1,497.78
Loading...
Loading...

About

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
102

Frequently Asked Questions

What is Market Cap of Spyre Therapeutics Inc.?
What is the 52-week high for Spyre Therapeutics Inc.?
What is the 52-week low for Spyre Therapeutics Inc.?
What is Spyre Therapeutics Inc. stock price today?
What was Spyre Therapeutics Inc. stock price yesterday?
What is the PE ratio of Spyre Therapeutics Inc.?
What is the Price-to-Book ratio of Spyre Therapeutics Inc.?
What is the 50-day moving average of Spyre Therapeutics Inc.?
How many employees does Spyre Therapeutics Inc. have?

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available